Labs Should Be Wary of Improper Billing of G0483 Testing
Recent OIG report says Medicare could have saved up to $215.8 million on at-risk payments for G0483 definitive drug tests.
Recent OIG report says Medicare could have saved up to $215.8 million on at-risk payments for G0483 definitive drug tests.
Recently announced enforcement actions saw three big settlements, with two of those coming from medical centers.
Labs may be billing Medicare for high-reimbursing and medically unnecessary drug tests, according to the OIG.
Though labs were again absent from recent key enforcement actions, sentences were handed down in other healthcare-related cases.
Though last week’s cases didn’t involve labs or lab testing, most were FCA-related issues including inflated claims.